Adipotide, also abbreviated FTPP (fat-targeted proapoptotic peptide), is a synthetic chimeric peptidomimetic that combines a white-adipose-tissue vascular homing motif with a pro-apoptotic effector sequence; in published preclinical work it was designed to bind endothelial cells lining fat vasculature and trigger local programmed cell death, making it a model molecule for vascular-targeted peptide research rather than an approved therapeutic. The published reference construct is commonly written CKGGRAKDC-GG-D(KLAKLAK)2, in which the homing motif recognizes prohibitin on adipose-tissue endothelium and the cationic amphipathic effector segment drives apoptosis of targeted cells (Kolonin et al., Nat Med 2004, PMID 15133506). This guide summarizes the research history, structure rationale, reported preclinical findings, experimental-design considerations and catalog sourcing checks. It contains no dosing or administration recommendation for humans or animals; catalog material is for laboratory research only.
Discovery and research history
The concept of homing peptides that home to organ-specific blood vessels predates adipotide itself. In 2004, Kolonin and colleagues reported in Nature Medicine that a peptide selected through in vivo phage display could home to white adipose tissue vasculature and, when fused to a pro-apoptotic effector sequence, reverse diet-induced obesity in mouse models by targeted ablation of fat-supporting vessels (PMID 15133506). The construct later became known as adipotide (FTPP).
Follow-up preclinical work extended the model in two directions. First, rodent studies examined how reducing adipose vasculature changed food intake, energy balance and neuroendocrine signals, rather than only measuring body weight (PMC2844838). Second, a non-human-primate study in obese rhesus macaques reported changes in body composition and insulin-related measures after a defined research dosing schedule, illustrating the molecule’s transition from mouse models toward larger-animal biology (Barnhart et al., Sci Transl Med 2011, PMC3666164). A later study specifically examined glucose-tolerance changes after adipose-endothelium targeting, asking whether vascular ablation impaired metabolic regulation rather than simply reducing mass (PMID 22733798).
Structural design: two domains plus a linker
Adipotide’s interest comes from its modular architecture, which is instructive for peptide-targeting research:
1. Homing domain (CKGGRAKDC-type motif): selected for binding to prohibitin displayed on the endothelium of white adipose tissue; this motif provides tissue selectivity rather than a systemic toxin effect.
2. Effector domain (D(KLAKLAK)2-type pro-apoptotic sequence): a cationic, amphipathic sequence that disrupts mitochondrial membranes and activates apoptotic signaling once internalized by the targeted endothelial cell.
3. Linker region: a short spacer allowing each domain to function independently; linker length and composition are variables that can be tested in analog design.
A key analytical point for catalog material: the homing motif and effector peptide are synthesized separately in chemical terms, and sequence integrity of both domains matters. A supplier CoA should support intact mass and, where possible, sequence-level confirmation; mixing up the homing motif with a different effector would change the molecule’s research identity entirely.
What the preclinical literature actually reported
Research conclusions should stay within what each model showed:
- Mouse obesity models: the foundational 2004 report described targeted adipose-vessel ablation and substantial fat-mass reduction in obese mice; the 2011 rodent follow-up characterized accompanying changes in feeding and endocrine regulation (PMC2844838).
- Non-human primates: the 2011 macaque study reported body-weight and body-fat changes alongside insulin-sensitivity measures after a research dosing schedule, with partial reversal during a recovery period; these are species-specific observations, not predictions for humans (PMC3666164).
- Metabolic readouts: the glucose-tolerance follow-up focused on whether adipose-vessel targeting altered glucose regulation, a question distinct from weight change alone (PMID 22733798).
Because vascular ablation can affect perfusion and organ function, preclinical reports also flagged monitoring considerations around renal and cardiovascular endpoints; researchers designing assays should build viability, perfusion and safety-marker controls rather than relying on body-weight endpoints alone.
Modern research angles beyond weight loss
Contemporary interest in adipotide-like chemistry includes:
- Vascular-targeting platform design: using homing peptides to deliver effector sequences to defined endothelial beds, a concept applied in tumor-vasculature and inflammation models.
- Peptide conjugate methodology: testing linker stability, serum proteolysis and intracellular release in cell-culture and ex-vivo assays.
- Analytical method development: LC-MS/MS identification of chimeric peptides, impurity profiling and counterion/basis verification.
- Comparative metabolic-peptide panels: researchers may place adipotide alongside metabolic reagents such as semaglutide research peptide when designing hypothesis-driven comparison sets, while keeping mechanisms clearly separated.
Catalog specifications and QC expectations
The adipotide research peptide listing supplies lyophilized powder in a 5 mg × 10-vial configuration (confirm the live variant on the product page). A lot review should request:
- Intact-mass identity consistent with the chimeric construct’s expected mass range.
- HPLC/UPLC purity with method details and related-substance profile.
- Net content basis (free peptide versus salt) and residual moisture.
- Lot number, retest date and storage condition matching vial labels.
- Solubility notes for the planned buffer; chimeric amphipathic peptides can show formulation-dependent aggregation.
The site’s purity testing and CoA interpretation guide and reconstitution guide cover the lab-side documentation practices these materials require.
Compliance boundary
Adipotide has no approved human indication. Catalog powder here is a research reagent for nonclinical experiments; it must not be administered to humans or animals as a treatment, and no clinical-use conclusion should be drawn from preclinical animal literature. Researchers remain responsible for institutional review, procurement compliance, chemical handling and waste disposal.
Frequently Asked Questions
What is adipotide?
Adipotide (FTPP) is a synthetic chimeric peptide combining an adipose-vascular homing motif with a pro-apoptotic effector sequence, studied in preclinical models of adipose vasculature.
Who discovered adipotide?
The targeted-adipose-ablation concept traces to Kolonin and colleagues’ Nature Medicine report in 2004; later work included rodent feeding studies and a rhesus-macaque preclinical study in 2011.
How does adipotide’s structure work conceptually?
A homing domain binds prohibitin on fat-vessel endothelial cells; an effector domain then triggers apoptosis in the targeted cell. The linker lets the two domains act independently.
What did preclinical studies report?
Mouse studies described fat-vessel targeting and weight/fat reduction; the primate study reported body-composition and insulin-related changes after a research dosing schedule. Results are species-specific and preliminary.
Is adipotide approved for human use?
No. It has no approved human indication; catalog material is sold for laboratory research only, without dosing or administration guidance.
What QC documents should be requested?
Intact-mass identity, chromatographic purity with methods, net content basis, related-substance data and full lot traceability; verify the configuration on the product page before ordering.
How does it relate to GLP-1 research peptides?
They are different mechanistic families; adipotide targets vasculature biology, while GLP-1 reagents target incretin receptors. Comparison experiments should keep controls and endpoints separate.
View Adipotide for Research: adipotide research peptide catalog listing · lyophilized powder with lot CoA available on request · worldwide shipping · laboratory research only; not for human or animal use.
